source
- Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filingCelldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
- Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officerAilux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…